Adamas Pharmaceuticals is developing novel therapeutics for the treatment of central nervous system (CNS) disorders by optimizing the pharmacokinetic profiles of approved drugs, alone and as components of fixed-dose combination products. The Company is currently advancing a pipeline of aminoadamantane-based drug candidates for the treatment of Parkinson’s disease, Alzheimer’s disease and other CNS disorders, with multiple product candidates in late-stage clinical development including:

• ADS-5102 (amantadine HCl ER) for CNS disorders, initially being investigated for levodopa-induced dyskinesia (LID) in Parkinson's disease;
• MDX-8704 (memantine HCl ER/donepezil HCl), being investigated for the treatment of moderate to severe dementia of the Alzheimer's type, being developed in collaboration with Forest Laboratories, Inc. (US market);
• ADS-8704 (memantine HCl ER/donepezil HCl), being investigated for the treatment of moderate to severe dementia of the Alzheimer's type (ex-US market).

Adamas' experienced team has developed an integrated process that combines in-depth knowledge of CNS markets and unmet medical needs, the interactions between drug plasma concentrations and clinical effects, regulatory strategy and pharmaceutical development to identify, optimize, protect and then develop proprietary controlled-release and fixed-dose combination products. The Company's current product candidates are based on an understanding of the relationship between blood level changes and side effects that may result in extended-release products with higher dose strengths than immediate-release formulations of aminoadamantanes.

Adamas has established a substantial intellectual property portfolio encompassing pharmacokinetics, compositions and methods of use for extended-release amantadine and memantine products. Adamas plans to advance its product candidates through approval and commercialize products in the United States through a specialty CNS sales force.

In addition to our CNS programs, Adamas is developing ADS-8902, (amantadine HCl/ oseltamivir/ribavirin) for the treatment of severe influenza infection in collaboration with the National Institutes of Health and US Navy. ADS-8902 exploits amantadine's second mode of action as an antiviral, which, when combined with oseltamivir and ribavirin, blocks influenza replication at multiple points in the virus life cycle.

Back to top »